Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2011-06-28
2011-06-28
Ewoldt, Gerald (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S143100, C530S388150, C530S388220
Reexamination Certificate
active
07968092
ABSTRACT:
The present invention provides human binding molecules that specifically bind to CD1a, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the human binding molecules. The human binding molecules can be used in the diagnosis, prevention and treatment of neoplastic disorders and diseases.
REFERENCES:
patent: 2001/0051156 (2001-12-01), Zeng et al.
patent: 2003/0211553 (2003-11-01), Logtenberg et al.
patent: WO 01/82960 (2001-11-01), None
patent: WO 02/06347 (2002-01-01), None
patent: WO 2005/063819 (2005-07-01), None
De Pascalis et al (J. Immunol. 2002, 169: 3076-3084).
Casset et al (2003, BBRC 307: 198-205).
Bechan et al (Blood Nov. 2005, 106: 4815).
Rudikoff et al, PNAS USA 1982, 79: 1979-1983.
Panka et al, PNAS USA 85: 3080-3084 1988.
Amit et al, Science, 233, 747-753, 1986.
Evolutionary Concepts in Genetics and Genomics. 2003, worldwideweb at.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=sef&part=A22.
PCT International Search Report, PCT/EP2004/053639, dated Aug. 30, 2005.
Amiot et al., “HLA class I molecules are associated with CD1 a heavy chains on normal human thymus cells,” Proc. Natl. Acad. Sci., Jun. 1988, pp. 4451-4545, vol. 85.
Vaughan et al., “Human antibodies by design,” Nature Biotechnology, Jun. 1998, pp. 535-539, vol. 16.
Dezutter-Dambuyant et al., DMC1 : A Monoclonal Antibody Produced from Histiocytosis X Cells Which Reacts with the Native CD1a Molecule of Human Epidermal Langerhans Cells, Hybridoma, 1989, vol. 8, No. 2, Mary Ann Liebert, Inc., Publishers.
Moulon et al., A Potential Role for CD1 a Molecules on Human Epidermal Langerhans Cells in Allogeneic T-Cell Activation, The Journal of Investigative Dermatology, Sep. 1991, pp. 524-28, vol. 97 No. 3, The Society for Investigative Dermatology, Inc.
Murray et al., Diagnostic and Therapeutic Evaluation of an Anti-Langerhans Cell Histiocytosis Monoclonal Antibody (Na1/34) in a New Xenograft Model, The Journal of Investigative Dermatology, Jan. 2000, pp. 127-134, vol. 114, No. 1, The Society for Investigative Dermatology, Inc.
Amiot M., Bernard A., Raynal B., Knapp W., Deschildre C. and Boumsell L. (1986), J. Immunol. 136:1752-1757.
Boel E., Verlaan S., Poppelier M.J, Westerdaal N.A., Van Strijp J.A. and Logtenberg T. (2000), J. Immunol. Methods 239:153-166.
Burton D.R. and Barbas C. E. (1994) Adv. Immonol 57:191-280.
De Kruif J., Terstappen L., Boel E. and Logtenberg T. (1995). Proc. Natl. Acad. Sci. USA 92:3938-3942.
De Kruif J., Boel E. and Logtenberg T. (1995). J. Mol. Biol. 248:97-105.
Fidler I.I. Gerstern D.M. and Budmen M. B. (1976), Cancer Research 36:3610-3165.
Furue M., Nindl M., Kawabe K., Nakamura K., Ishibashi Y. and Sagawa K. (1992), J. Am. Acad. Dermatol. 27:419-426.
Ghetie M.A., Bright H. and Vitetta E.S. (2001), Blood 97:1392-1398.
Huls G., Heijnen I.J., Cuomo E., van der Linden J., Boel E., van de Winkel J. and Logtenberg T. (1999), Cancer Res. 59:5778-5784.
Jonuleit H., Kühn U., Müller G., Steinbrink K., Paragnik L., Schmitt E., Knop J., Enk A.H. (1997), Eur. J. Immunology 27:3135-3142.
Kelly K.M., Beverly P.C., Chu A.C., Davenport V., Gordon I., Smith M. and Pritchard J. (1994), J. Pediatr. 125:717-722.
Merle-Beral H., Boumsell L. Michel A. and Dehre P. (1989) Br. J. Haematol 72:209-212.
Salomone M.C. Roisman E.R. Santiago J., Satz M. L. and Fainboim L. (1990) Dis. Markers 8:265-274.
Salomone M.C. Roisman E.R. Santiago J., Satz M. L. and Fainboim L. (1990) Dis. Markers 8:275-281.
Teunissen M.B. (1992) Histochem. J. 24:697-716.
Van Kroonenburgh M.J. and Pauwels E.K. (1988) Nucl. Med Commun. 9:919-910.
U.S. Appl. No. 11/990,974, Feb. 21, 2008, Method for Preparing Immunoglobulin Libraries, Throsby et al.
U.S. Appl. No. 12/227,029, Nov. 5, 2008, Human Binding Molecules Having Killing Activity AgainstStaphylococciand uses Thereof, Throsby et al.
U.S. Appl. No. 12/227,116, Nov. 7, 2008, Human Binding Molecules Having Killing Activity AgainstEnterococciand Uses Thereof, Throsby et al.
U.S. Appl. No. 12/310,812, Mar. 6, 2009, Human Binding Molecules Capble of Neutralizing Influenza Virus H5N1 and Uses Thereof, Van den Brink et al.
U.S. Appl. No. 61/215,890, May 11, 2009, Human Binding Molecules Capable of Neutralizing Influenza virus H3N2 and Uses Therof, Throsby et al.
O'Brien et al., Humanization of Monoclonal Antibodies by CDR Grafting, Methods in Molecular Biology, pp. 81-100, Sep. 16, 2002, vol. 207, Chapter 5, Totowa, NJ, USA.
Arceci Robert J.
Germeraad Wilfred T. V.
Kruisbeek Ada M.
Throsby Mark
van Meijer Marja
Crucell Holland B.V.
DiBrino Marianne
Ewoldt Gerald
The Johns Hopkins University
TraskBritt P.C.
LandOfFree
Human binding molecule against CD1a does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human binding molecule against CD1a, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human binding molecule against CD1a will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2726745